TMO:NYSEThermo Fisher Scientific Inc Analysis

Technical outlook: TMO trades at $456.21, below its 20‑day SMA (457.22) and well under its 50‑day (478.76) and 200‑day (526.58) averages, indicating a short‑term bearish bias. Momentum indicators show an RSI of 45 (neutral) and a positive MACD histogram, giving a modest bullish signal amid the downtrend. Volatility is high at 36.8% over the past 30 days and beta of 0.93 suggests price moves close to the market. Fundamentals are robust: revenue grew 6.2% YoY to $45.2 B, gross margin is 40.9%, operating margin 17.9%, and free cash flow exceeds $5.5 B. The forward EPS of $27.30 translates to a forward P/E of 16.7, well below the industry average of 27.4, and analysts’ consensus target price is around $613, implying a 34% upside. Dividend yield is modest at 0.41% with a payout ratio under 10%, supporting dividend sustainability.
Balance sheet & growth catalysts: The balance sheet shows $3.26 B in cash against $43.16 B of debt, yielding a debt‑to‑equity of 82.9, which elevates financial risk but is mitigated by strong operating cash flow of $8.3 B. Recent news highlights a 6.2% revenue increase in Q1, a successful technology transfer for the Ibtrozi lung‑cancer therapy, and the opening of a new Bioprocess Design Center, underscoring expanding biopharma manufacturing capabilities. Investor sentiment is bullish, reflected in a “Strong Buy” consensus and an “Extreme Greed” market mood (Fear‑Greed Index 91.5). While the DCF‑derived fair value of $147 suggests the stock is priced far above intrinsic estimates, the forward‑looking earnings growth and strategic initiatives justify a fair‑to‑growth valuation stance. Overall, the stock appears positioned for a medium‑ to long‑term rally, with short‑term price pressure likely to persist until momentum shifts.